BNY Mellon (BK) price targets set by KBW and RBC Capital


The Bank of New York Mellon Corporation (NYSE:BK) is one of the The 11 Most Profitable Cheap Stocks to Invest Now. On January 14, Keefe, Bruyette & Woods increased their price target on The Bank of New York Mellon Corporation (NYSE:BK) from $132 to $143 and maintained their outperform rating.

The research firm highlighted The Bank of New York Mellon Corporation’s (NYSE:BK) strong performance in its latest quarter and pointed to new mid-term profitability targets. These include a pre-tax margin of 38% or more and a return on tangible equity (ROTCE) of 28% or more.

BNY Mellon (BK) price targets set by KBW and RBC Capital
BNY Mellon (BK) price targets set by KBW and RBC Capital

Keefe, Bruyette & Woods raised its EPS estimates for The Bank of New York Mellon Corporation (NYSE:BK) for 2026 and 2027. The firm also noted that the company’s progress toward high ROTCE of 20% and growing net interest margin could allow for multiple expansion.

Also on January 14, RBC Capital increased its price target on The Bank of New York Mellon Corporation (NYSE:BK) from $124 to $130 and maintained its sector perform rating. The research firm noted that the company’s “laser focus” on execution, which is the company’s “Northstar” metric, helps achieve positive operating leverage.

The Bank of New York Mellon Corporation (NYSE:BK) is a leading financial services company that provides financial platforms, products and services in the United States and internationally.

While we recognize BK’s potential as an investment, we believe certain AI stocks offer greater upside potential and less downside risk. If you’re looking for an extremely undervalued AI stock that will also benefit significantly from Trump-era tariffs and the onshoring trend, check out our free report on the best short term AI stock.

READ THE FOLLOWING: 12 Best 5G Stocks to Invest According to Hedge Funds i 12 Best US Energy Stocks to Buy Now.

Disclosure: no. This article is originally published in Monkey Insider.



Source link

  • Related Posts

    Client Challenge

    Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to continue. A required part of this site could not load. This could be due to a browser extension,…

    China’s CSPC Pharmaceutical, AstraZeneca’s long-acting obesity drug partner

    China’s CSPC Pharmaceutical, AstraZeneca’s long-acting obesity drug partner Source link

    Leave a Reply

    Your email address will not be published. Required fields are marked *